文献速递心力衰竭与心肌病

NT-proBNP与高强度治疗在急性心衰中的应用:STRONG-HF试验

NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial.
PubMed 文献 · Eur Heart J · 2023-01-01

STRONG-HF试验显示高强度治疗(HIC)快速上调指南推荐药物治疗(GRMT)优于常规治疗。本研究分析1077例急性心衰住院患者,按随机化后1周NT-proBNP变化分层,发现HIC的获益与基线NT-proBNP无关;出院后早期NT-proBNP升高者接受更多利尿剂并减慢上调速度,180天结局无差异。

要点

  • HIC减少180天心衰再入院或死亡,与基线NT-proBNP水平无关。
  • 早期NT-proBNP升高者接受更多利尿剂和更慢上调,180天结局与降低者无差异。
  • 早期NT-proBNP变化可用于指导利尿剂和GRMT上调速度。

核心结论

  • 在STRONG-HF试验的急性心衰患者中,HIC减少180天心衰再入院或死亡,无论基线NT-proBNP水平如何。
  • 出院后早期以NT-proBNP升高为指导增加利尿剂并降低GRMT上调速度,使得无论早期NT-proBNP变化如何,180天结局相同。

研究设计与样本

  • STRONG-HF试验的事后分析,纳入1077例因急性心衰住院且从筛查(入院)至随机化(出院前)NT-proBNP下降>10%的患者。
  • HIC组患者根据随机化至1周后NT-proBNP变化分为降低(≥30%)、稳定(<30%下降至≤10%升高)或升高(>10%)。
  • 主要终点为180天心衰再入院或死亡。

主要发现

  • HIC与常规治疗的效果与基线NT-proBNP无关。
  • HIC组中NT-proBNP稳定或升高的患者年龄更大,急性心衰更严重,肾功能和肝功能更差。
  • 按方案,NT-proBNP升高者接受更多利尿剂,出院后最初几周GRMT上调更慢;6个月时达到70.4%最佳GRMT剂量,而NT-proBNP降低者为80.3%。
  • 60天和90天主要终点在NT-proBNP升高者中分别为8.3%和11.1%,在降低者中分别为2.2%和4.0%(P=0.039和P=0.045)。
  • 180天结局无差异(13.5% vs 13.2%;P=0.93)。

关键数值与推荐

  • 纳入标准:因急性心衰住院且从筛查至随机化NT-proBNP下降>10%。
  • NT-proBNP变化分层:降低≥30%,稳定<30%下降至≤10%升高,升高>10%。
  • 主要终点:180天心衰再入院或死亡。

临床怎么用

  • 对于急性心衰住院患者,出院后早期可依据NT-proBNP变化指导治疗:升高者增加利尿剂并减慢GRMT上调速度。
  • HIC策略的获益不受基线NT-proBNP水平影响,可考虑用于广泛急性心衰患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: STRONG-HF showed that rapid up-titration of guideline-recommended medical therapy (GRMT), in a high intensity care (HIC) strategy, was associated with better outcomes compared with usual care. The aim of this study was to assess the role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) at baseline and its changes early during up-titration. METHODS AND RESULTS: A total of 1077 patients hospitalized for acute heart failure (HF) and with a >10% NT-proBNP decrease from screening (i.e. admission) to randomization (i.e. pre-discharge), were included. Patients in HIC were stratified by further NT-proBNP changes, from randomization to 1 week later, as decreased (≥30%), stable (<30% decrease to ≤10% increase), or increased (>10%). The primary endpoint was 180-day HF readmission or death. The effect of HIC vs. usual care was independent of baseline NT-proBNP. Patients in the HIC group with stable or increased NT-proBNP were older, with more severe acute HF and worse renal and liver function. Per protocol, patients with increased NT-proBNP received more diuretics and were up-titrated more slowly during the first weeks after discharge. However, by 6 months, they reached 70.4% optimal GRMT doses, compared with 80.3% for those with NT-proBNP decrease. As a result, the primary endpoint at 60 and 90 days occurred in 8.3% and 11.1% of patients with increased NT-proBNP vs. 2.2% and 4.0% in those with decreased NT-proBNP (P = 0.039 and P = 0.045, respectively). However, no difference in outcome was found at 180 days (13.5% vs. 13.2%; P = 0.93). CONCLUSION: Among patients with acute HF enrolled in STRONG-HF, HIC reduced 180-day HF readmission or death regardless of baseline NT-proBNP. GRMT up-titration early post-discharge, utilizing increased NT-proBNP as guidance to increase diuretic therapy and reduce the GRMT up-titration rate, resulted in the same 180-day outcomes regardless of early post-discharge NT-proBNP change.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Adamo, Pagnesi, Mebazaa, et al. NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial. Eur Heart J. 2023. PMID: 37217188. doi:10.1093/eurheartj/ehad335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。